Malaria is most prevalent in tropical climate and causes 1–3 million deaths annually. RIO-2 kinase, an atypical kinase regulates ribosome biogenesis and is necessary for cell cycle progression. Structural characterization of PFD0975w (PfRIO-2 kinase) indicates N-terminal DNA binding winged helix domain (1–84), a linker region (85–147), and C-terminal kinase domain (148–275). Heterocyclic compounds present in different databases represent an enormous reservoir to screen and develop the suitable inhibitor. An extensive screening of heterocyclic compounds present in zinc database, PubChem and ChemBank database was done to identify potent PfRIO-2 kinase specific inhibitors. Initial screening gave 41 compounds with high affinity toward PfRIO-2 kinase than natural substrate ATP. A substrate competition experiment and analysis of binding mode conformation within the ATP binding pocket identifies five compounds; Zc-49775260, Pc-44415375, Pc-44215930, Cb-2082655, and Cb-832054 as potential PfRIO-2 kinase inhibitors. Further analysis of top hits in ADMET parameters, Caco-2 cell permeability profile, human oral absorption, and drug-like properties indicates Pc-44215930 as the best suitable compound among the top hits. Searching top hits candidate heterocyclic compounds in the drug database picked up clindamycin, nelfinavir, methacycline, and other drugs in circulation. Most of these drugs are targeting ribosome maturation and highlights the possibility of PfRIO-2 kinase as a drug target. Hence, screening and substrate competition studies along with ADME analysis of top hit compounds allowed us to identify potential PfRIO-2 kinase inhibitors. We are hopeful that the current study will help to develop effective chemotherapy against malaria utilizing PfRIO-2 kinase as a target.
Read full abstract